LBL1
LBL1 is a Lamin A inhibitor with a Kd of 5.11 μM for LA (1-387). LBL1 directly binds to Lamin A and disrupts the Lamin A-Rad51 interaction, accelerates proteasome-mediated Rad51 degradation, and induces DNA double-strand breaks. LBL1 induces Apoptosis. LBL1 serves as a chemical tool for studying lamin biology and the post-translational regulation of Rad51. LBL1 can be used in studies related to breast cancer and non-small cell lung cancer.
For research use only. We do not sell to patients.
- CAS No.: 1605301-58-3
- Formula: C21H15N5O
- Molecular Weight:353.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MDA-MB-231 | GI50 |
1.6 μM
Compound: 7f
|
Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay
Growth inhibition of human MDA-MB-231 cells after 72 hrs by MTT assay
|
[PMID: 24163729] |
| MDA-MB-468 | GI50 |
0.44 μM
Compound: 7f
|
Growth inhibition of human MDA-MB-468 cells after 72 hrs by MTT assay
Growth inhibition of human MDA-MB-468 cells after 72 hrs by MTT assay
|
[PMID: 24163729] |
In Vitro
LBL1 (100 μM; 30 min) does not intercalate into DNA even at concentrations as high as 100 μM[1].
LBL1 (2.5-5.0 μM; 24 h) does not induce phosphorylation of histone H2AX (γ-H2AX) in normal primary foreskin fibroblasts at concentrations up to 5.0 μM with a 24 h treatment duration[1].
LBL1 (2.5 μM; 24 h) does not reduce Rad51 mRNA levels in MDA-MB-231 human breast cancer cells, which indicates that Rad51 is subject to post-translational regulation[1].
LBL1 (1-100 μM; 1 h) dose-dependently induces higher-order oligomerization of purified recombinant LA (1−387) in vitro[2].
LBL1 binds to the purified recombinant lamin A fragment LA (1-387), with an apparent dissociation constant Kd of 5.11 μM. This result is confirmed by the dose-dependent increase in the first melting temperature of the protein[3].
LBL1 (0-2.5 μM; 48 h) dose-dependently arrests the breast cancer cell line MDA-MB-231 at the G2/M phase, and induces G1 peak broadening at concentrations up to 2.5 μM following 48 h of treatment, a phenomenon consistent with the formation of DNA double-strand breaks[1].
LBL1 significantly increases the number of γ-H2AX foci-positive MDA-MB-231 breast cancer cells, indicating the formation of DNA double-strand breaks[1].
LBL1 (30 h) induces significant double-strand DNA breaks in breast cancer MDA-MB-231 cells, a result verified by the increased tail DNA content in neutral comet assays[1].
LBL1 (0-2.5 μM; 24 h) induces proteasome-mediated degradation of the Rad51 protein in breast cancer MDA-MB-231 cells[1].
LBL1 (72 h) inhibits the growth of MDA-MB-468 and MDA-MB-231 breast cancer cells, with GI50 values of 0.44 μM and 1.60 μM against the two cell lines respectively after 72 h of incubation[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-231 human breast cancer cells
-
Concentration:0-2.5 μM
-
Incubation Time:48 h
-
Result:Dose-dependently arrested cells at the G2/M phase, with a concomitant decrease in G1 and S phase cell populations.
Increased the coefficient of variance (CV%) of the G1 peak from 8.8 (DMSO control) to 12.82 (P < 0.05), indicative of DNA double-strand break (DSB) formation.
-
Cell Line:MDA-MB-231 human breast cancer cells
-
Concentration:2.5 μM
-
Incubation Time:24 h
-
Result:Caused no significant change in Rad51 mRNA levels compared to DMSO control cells.
Chemical Information
-
CAS No. 1605301-58-3
-
Molecular Weight 353.38
-
Formula C21H15N5O
-
SMILES
O=C(C1=CC=C2C=CC=CC2=C1)NC3=NC(N)=C4C5=C(NC=C5)C=CC4=N3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
Purity & Documentation
References
[1]. Li BX, et al. A Lamin-Binding Ligand Inhibits Homologous Recombination Repair of DNA Double-Strand Breaks. ACS central science. 2018 Sep 26;4(9):1201-1210. [Content Brief]
[2]. Wang J, et al. CG-SLENP: A Chemical Genetics Strategy To Selectively Label Existing Proteins and Newly Synthesized Proteins. JACS Au. 2024 Jul 25;4(8):3146-3156. [Content Brief]
[3]. Li BX, et al. Anticancer Pyrroloquinazoline LBL1 Targets Nuclear Lamins. ACS chemical biology. 2018 May 18;13(5):1380-1387. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- LBL1
- 1605301-58-3
- LBL 1
- LBL-1
- DNA/RNA Synthesis
- RAD51
- Apoptosis
- Rad51
- lamin A
- DNA double-strand breaks
- homologous recombination repair
- HEK 293T human embryonic kidney cells
- breast cancer
- proteasome-mediated degradation
- nonsmall cell lung cancer
- MDA-MB-231 human breast cancer cells
- cellular apoptosis
- Inhibitor
- inhibitor
- inhibit